Susquehanna Portfolio Strategies’s Keros Therapeutics KROS Stock Holding History

Susquehanna Portfolio Strategies’s Portfolio KROS Stock Details KROS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$480K	Buy	+44,824	New	+$499K	0.01%	673

Other funds holding KROS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Susquehanna Portfolio Strategies's KROS Position: Q2 2026 in Review

Susquehanna Portfolio Strategies opened a new position in Keros Therapeutics (KROS) in Q2 2026: 44,824 shares worth $480K. The stake represents 0.01% of the portfolio and ranks #673 among its holdings.

132 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

Susquehanna Portfolio Strategies held 44,824 shares of Keros Therapeutics worth $480K as of Q2 2026.
Keros Therapeutics was a new Susquehanna Portfolio Strategies position in Q2 2026.
Keros Therapeutics made up 0.01% of Susquehanna Portfolio Strategies's portfolio in Q2 2026, its #673 holding.
132 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on Susquehanna Portfolio Strategies's 13F filing for Q2 2026, filed 14 Aug 2026.